Welcome to our dedicated page for Hcw Biologics news (Ticker: HCWB), a resource for investors and traders seeking the latest updates and insights on Hcw Biologics stock.
HCW Biologics Inc. develops fusion immunotherapeutics for diseases associated with chronic inflammation, including autoimmune disorders, proinflammatory diseases, cancer and senescence-associated dysplasia. Its recurring company updates center on the TOBI and TRBC discovery platforms and product candidates such as HCW9302, an IL-2 fusion immunotherapeutic, HCW11-018b, a T-cell engager for solid tumors, and HCW9206, a multi-cytokine fusion protein reagent used in CAR-T manufacturing research.
News about HCWB also covers clinical and preclinical program disclosures, research publications, licensing activity involving HCW11-006 and Trimmune, operating and financial results, capital-structure matters, shareholder voting topics and Nasdaq listing-status developments.
HCW Biologics (NASDAQ: HCWB), a clinical-stage biopharmaceutical company, has successfully regained compliance with all Nasdaq Capital Market listing requirements. The company received confirmation from Nasdaq on June 24, 2025 that it met the minimum stockholders' equity requirement (Rule 5550(b)(1)).
Previously, on May 13, 2025, HCWB had already regained compliance with other crucial requirements including bid price (Rule 5550(a)(2)), public float (Rule 5550(a)(4)), and market value of publicly held shares (Rule 5550(a)(5)). The company, which focuses on developing innovative immunotherapies targeting chronic inflammation, is now fully compliant for continued listing on the Nasdaq Capital Market.
HCW Biologics (NASDAQ: HCWB) reported its Q1 2025 financial results and completed a $5.0 million equity offering with an institutional investor. The company's Q1 2025 revenues decreased to $5,065 from $1.1 million in Q1 2024, while net loss improved to $2.2 million from $7.5 million. R&D expenses decreased 30% to $1.5 million, while G&A expenses increased 42% to $2.2 million.
Key developments include FDA clearance for a Phase 1 trial of HCW9302 for alopecia areata, and an expected $7.0 million upfront licensing fee from WY Biotech for HCW11-006. The company regained Nasdaq compliance but must meet all listing requirements by June 16, 2025. Management expressed concerns about the company's ability to continue as a going concern without additional funding.
HCW Biologics (NASDAQ: HCWB) has announced the pricing of a $5.0 million follow-on offering at $7.45 per unit. Each unit includes one share of common stock (or pre-funded warrant) and two warrants to purchase common stock. The warrants have an exercise price of $7.45 per share, are immediately exercisable, and expire in five years.
The offering is expected to close around May 15, 2025, with Maxim Group LLC acting as sole placement agent. The company plans to use the proceeds for preclinical and clinical development of HCW9302, business development, patent portfolio expansion, and general corporate purposes. Additionally, HCWB has agreed to reduce the exercise price of certain existing warrants from $41.20 to $7.45 per share.
HCW Biologics (NASDAQ: HCWB) has announced positive results for its proprietary fusion protein HCW9206, demonstrating superior performance in generating CAR-T cells for immunotherapy. The compound shows significant advantages over standard methods using anti-CD3/anti-CD28 and IL-2 reagents for CAR lentiviral transduction.
Research presented at the 2025 Annual Meeting of American Association of Immunologists revealed that HCW9206 effectively expands stem cell-like memory T cells (Tscm) carrying CAR constructs, which exhibit better persistence and targeted cell killing. In experimental humanized mouse models, HCW9206-generated CAR-Ts showed enhanced potency in suppressing HIV-1 and leukemic cells compared to standard methods.
The company has completed the GMP master cell bank and manufacturing process for HCW9206, with its drug master file submitted to the FDA. HCWB is now seeking commercial partnerships for reagent sales and integration into CAR-T manufacturing processes.
HCW Biologics (NASDAQ: HCWB) has announced a 1-for-40 reverse stock split effective April 11, 2025, aimed at regaining compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The reverse split will reduce the company's outstanding shares from 44,934,120 to approximately 1,123,353, while maintaining the total authorized shares at 250,000,000.
The split will uniformly affect all stockholders without altering their percentage ownership, except for fractional shares which will be rounded up to one whole share. The company's common stock will continue trading under the symbol 'HCWB' with a new CUSIP number 40423R204. The split will proportionally adjust equity incentive plans, stock options, and warrants, including their exercise prices.
HCW Biologics (NASDAQ: HCWB) reported its Q4 and fiscal year 2024 results, highlighting significant developments in its immunotherapy pipeline. The company received FDA clearance to begin Phase 1 trials for HCW9302 in alopecia areata treatment. A notable licensing agreement with WY Biotech is expected to bring in $7.0 million in June 2025.
Financial highlights include raising $16.3 million in 2024 through various transactions. However, revenues decreased from $1.3 million in Q4 2023 to $394,000 in Q4 2024. The company's net loss increased from $25.0 million in 2023 to $30.0 million in 2024, largely due to legal expenses.
The company faces Nasdaq compliance challenges and must meet listing requirements by April-June 2025. Management acknowledges substantial doubt about continuing operations without additional funding, though financing activities are underway with Maxim Group as Placement Agent.
HCW Biologics (HCWB) has received an extension from the Nasdaq Hearings Panel to maintain its listing on The Nasdaq Capital Market. The Panel's decision, announced on March 3, 2025, follows a hearing on February 13, 2025, where the company presented its compliance plan.
The extension requires HCWB to meet specific criteria: achieve minimum bid price compliance by April 25, 2025, and satisfy all other Exchange listing requirements by June 15, 2025. These requirements include compliance with market value of publicly held securities (MVPHS) and market value of listed securities (MVLS) rules.
HCW Biologics (NASDAQ: HCWB) has received FDA clearance for its Investigational New Drug Application to begin a first-in-human Phase 1 dose escalation clinical trial for HCW9302, targeting moderate-to-severe alopecia areata. This autoimmune disease causes sudden hair loss and currently lacks curative FDA-approved treatments.
HCW9302 is an injectable IL-2 fusion protein complex developed using the Company's TOBI platform technology. It works by binding to IL-2αβγ receptors on regulatory T cells (Treg), activating and expanding them to suppress unwanted immune and inflammatory responses. The drug has shown efficacy in treating autoimmune diseases through subcutaneous injections in preclinical models.
The initial trial aims to establish a safe dose that effectively increases Treg cell activity. Upon success, the company plans to expand into Phase 2 studies for other autoimmune diseases and inflammatory conditions, including dermatological conditions, graft rejection, arthrosclerosis, diabetes, and neurodegenerative diseases.
HCW Biologics (NASDAQ: HCWB) announced that its Founder and CEO, Hing C. Wong, Ph.D., will participate as a panelist at the 2025 GenScript Biotech Global Forum during J.P. Morgan Week in San Francisco. The panel discussion, focusing on Cell and Gene Therapy (CGT) challenges in biomanufacturing and supply chain management, will take place on January 15, 2025.
The company has developed subcutaneous immunotherapeutics using its drug discovery platform, categorized into three classes: Multi-Functional Immune Cell Stimulators, Second-Generation Immune Checkpoint Inhibitors and Multi-Specific Targeting Fusions, and Enhanced Immune-Cell Engagers. Dr. Wong will discuss how combining CGTs with their proprietary molecules could reduce costs and improve clinical efficacy of engineered effector cells. He will also present why Immune-Cell Engagers could potentially challenge cell-based therapies for cancer, autoimmune diseases, and aging-related conditions.